Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure

Nina Worel, Gerhard Fritsch, Hermine Agis, Alexandra Böhm, Georg Engelich, Gerda C Leitner, Klaus Geissler, Karoline Gleixner, Peter Kalhs, Veronika Buxhofer-Ausch, Felix Keil, Gerhard Kopetzky, Viktor Mayr, Werner Rabitsch, Regina Reisner, Konrad Rosskopf, Reinhard Ruckser, Claudia Zoghlami, Niklas Zojer, Hildegard T Greinix

Research output: Journal article (peer-reviewed)Journal article

26 Citations (Scopus)


Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF) is approved for autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or malignant lymphoma. The purpose of this study was to evaluate efficacy and safety of plerixafor in an immediate rescue approach, administrated subsequently to G-CSF alone or chemotherapy and G-CSF in patients at risk for mobilization failure. Eighty-five patients mobilized with G-CSF alone or chemotherapy were included. Primary endpoint was the efficacy of the immediate rescue approach of plerixafor to achieve ≥2.0 × 106 CD34+ cells/kg for a single or ≥5 × 106 CD34+ cells/kg for a double transplantation and potential differences between G-CSF and chemotherapy-based mobilization. Secondary objectives included comparison of stem cell graft composition including CD34+ cell and lymphocyte subsets with regard to the mobilization regimen applied. No significant adverse events were recorded. A median 3.9-fold increase in CD34+ cells following plerixafor was observed, resulting in 97% patients achieving at least ≥2 × 106 CD34+ cells/kg. Significantly more differentiated granulocyte and monocyte forming myeloid progenitors were collected after chemomobilization whereas more CD19+ and natural killer cells were collected after G-CSF. Fifty-two patients underwent transplantation showing rapid and durable engraftment, irrespectively of the stem cell mobilization regimen used. The addition of plerixafor in an immediate rescue model is efficient and safe after both, G-CSF and chemomobilization and results in extremely high success rates. Whether the differences in graft composition have a clinical impact on engraftment kinetics, immunologic recovery, and graft durability have to be analysed in larger prospective studies.

Original languageEnglish
Pages (from-to)224-234
Number of pages11
JournalJournal of Clinical Apheresis
Issue number4
Publication statusPublished - Aug 2017


  • Adult
  • Aged
  • Autografts/cytology
  • Benzylamines
  • Cyclams
  • Female
  • Granulocyte Colony-Stimulating Factor/therapeutic use
  • Hematopoietic Stem Cell Mobilization/methods
  • Hematopoietic Stem Cell Transplantation/methods
  • Heterocyclic Compounds/therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Premedication/methods
  • Prospective Studies
  • Transplantation, Autologous
  • Treatment Outcome


Dive into the research topics of 'Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure'. Together they form a unique fingerprint.

Cite this